+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Intravenous Solutions Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997392
  • Report
  • March 2020
  • Region: Global
  • 110 pages
  • Mordor Intelligence
1 of 4


  • Ajinomoto
  • Anhui Medipharm Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International
  • Fresenius Kabi AG
  • Grifols
  • MORE
The intravenous solutions market studied is projected to grow with a CAGR of nearly 4.3% over the forecast period. The major factor attributing to the growth of the market is the increase in the prevalence of diseases such as gastrointestinal diseases, Neurological diseases, Cancer, etc. where intravenous solutions are the main sources of energy for the patients. According to the World Health Organization, diarrhea is the second leading cause of death in children under five years old. Globally, there are nearly 1.7 billion cases of childhood diarrhea disease every year. Furthermore, product innovations such as introducing premixed solutions for better convenience and to reduce the amount of packaging waste, and availability of solutions in portable packages which becomes easier for the patients to use the drips at the comfort of their home rather than a hospital are few other factors boosting the market growth. However regulatory and quality requirements contribute additional cost and complexity to the market. Intravenous fluids are regulated as pharmaceutical products and carry all of the capital investment requirements of sterile injectable medications despite being sold at relatively low prices, which hinders the market growth.

Key Market Trends

Saline IV Segment is Dominating the Intravenous Solutions Market.

Sodium chloride 0.9%, with or without additional potassium, is one of the most commonly used IV fluids when fluid is lost for any reason, electrolytes become imbalanced, body systems are stressed, and cognitive function in the brain is impaired. Blood becomes concentrated, signalling the kidneys to retain water. As a result, urine output is decreased. Replacement of fluids intravenously resolves the imbalance and restores normal body functions. The saline fluid is used mainly in conditions like hemorrhage, vomiting, diarrhea, drainage from gastrointestinal suction, metabolic acidosis, or shock. It is the only fluid used in conjunction with blood product administration. All these factors make it the most used IV fluid maintaining its dominant position in the market.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of diseases like cancer, vomiting, diarrhea in the region, and established healthcare infrastructure. Furthermore, beneficial government initiatives and increase in the number of research partnerships are some of the drivers that are expected to increase the market growth. In this region the United States has the maximum share due to supportive healthcare policies, high number of patients, and a developed healthcare market. According to Centers for Disease Control and Prevention (CDC), Norovirus is the leading cause of vomiting and diarrhea among people of all ages in the United States. It is estimated that 19 to 21 million cases of acute gastroenteritis are caused due to the virus and contributes to about 56,000 to 71,000 hospitalizations and 570 to 800 deaths, mostly among young children and the elderly. Hence, the statistics indicate that the increasing patient pool and increasing disposable revenue in this country boosts the market growth of the region.

Competitive Landscape

The Intravenous Solutions market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Ajinomoto, B. Braun Melsungen AG, Baxter International, Grifols, ICU Medical, Inc., among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • Ajinomoto
  • Anhui Medipharm Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International
  • Fresenius Kabi AG
  • Grifols
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Diseases, such as Gastrointestinal Disorder, Neurological Diseases, Cancer, etc.
4.2.2 Advancements and New Innovations in the Products for Patient Convenience
4.3 Market Restraints
4.3.1 Regulatory and Quality Requirements
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Total Parenteral Nutrition
5.1.2 Peripheral Parenteral Nutrition
5.2 By Solution Composition
5.2.1 Saline
5.2.2 Carbohydrates
5.2.3 Vitamins and Minerals
5.2.4 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Ajinomoto
6.1.2 B. Braun Melsungen AG
6.1.3 Baxter International
6.1.4 Grifols
6.1.5 ICU Medical, Inc.
6.1.6 Fresenius Kabi AG
6.1.7 Omnicare
6.1.8 Anhui Medipharm Co., Ltd.
6.1.9 Wuhan Uni-Pharma Bio-Tech Co., Ltd.
Vifor Pharma

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Ajinomoto
  • B. Braun Melsungen AG
  • Baxter International
  • Grifols
  • ICU Medical, Inc.
  • Fresenius Kabi AG
  • Omnicare
  • Anhui Medipharm Co., Ltd.
  • Wuhan Uni-Pharma Bio-Tech Co., Ltd.
Vifor Pharma
Note: Product cover images may vary from those shown